Sone-214 May 2026

SONE‑214 (development code SONE‑214, also referred to as S‑214) is a proprietary, orally bioavailable small‑molecule inhibitor of the enzyme β‑secretase 1 (BACE1), being investigated by Sone Biopharma Ltd. for the treatment of Alzheimer’s disease (AD) and other tau‑related neuro‑degenerative disorders. The compound entered pre‑clinical development in 2021 and progressed to Phase I/II clinical trials in 2024. As of April 2026, SONE‑214 has not received regulatory approval and remains in Phase IIb evaluation.

| Year | Milestone | |------|-----------| | 2020 | Target validation of BACE1 for AD; Sone Biopharma initiates a hit‑to‑lead program. | | 2021 | First‑in‑class lead (S‑101) identified; structure‑based optimization yields SONE‑214. | | 2022 | Patent filed (WO 2022/134567 A1). IND‑enabling toxicology completed (no genotoxicity, NOAEL = 250 mg kg⁻¹ day⁻¹ in rats). | | 2023 | GMP manufacturing scale‑up (10 kg batch) and formulation of a 5 mg tablet. | | 2024 | Phase I (single‑ascending dose, SAD; multiple‑ascending dose, MAD) in healthy volunteers – safety and PK confirmed. | | 2025 | Phase IIa – 12‑week proof‑of‑concept (POC) study in mild‑to‑moderate AD (N = 84) – primary endpoint: change in CSF Aβ₄₂. | | 2026 | Phase IIb/III – Adaptive design trial (N = 420) evaluating cognitive outcomes (ADAS‑Cog13) and disease‑modifying biomarkers. | SONE-214

The Phase IIa data validated target engagement and informed the dose selection for the ongoing Phase IIb/III trial. SONE‑214 (development code SONE‑214, also referred to as

| Parameter | Value (healthy volunteers) | |-----------|-----------------------------| | Oral bioavailability | 68 % (fasted) | | C_max | 2.1 µM (after 50 mg dose) | | T_max | 2.5 h | | Half‑life (t_1/2) | 12.4 h (dose‑linear up to 200 mg) | | Volume of distribution (V_d) | 2.2 L kg⁻¹ | | Plasma protein binding | 96 % (albumin) | | BBB penetration | Unbound brain/plasma ratio ≈ 0.8 | | Clearance (CL) | 0.48 L h⁻¹ kg⁻¹ (primarily hepatic via CYP3A4) | | Metabolites | Two minor oxidative metabolites (M1, M2) cleared renally; no active metabolites detected. | | Year | Milestone | |------|-----------| | 2020

Pharmacodynamic markers (measured in cerebrospinal fluid, CSF) show a dose‑dependent reduction in Aβ₄₂ (up to 71 % at 100 mg BID) within 14 days of treatment.

SONE-214 has circulated in niche technical and industrial communities as a shorthand that can refer to either a specific product code, a material grade, or an internal project name depending on context. Below I outline plausible interpretations, technical characteristics, potential applications, and the strategic implications for teams working with—or encountering—something labeled SONE-214. I assume you want a blog-style, informative post aimed at a technical or business audience; if you meant a different tone or audience, tell me and I’ll adapt.